|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 3540 Crain Highway |
Address2 | Ste. 675 |
City | Bowie |
State | MD |
Zip Code | 20716 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 13723-12
|
||||||||
|
6. House ID# 333440000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Laura Weidner |
Date | 7/18/2022 6:26:32 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
-Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2023, support funding for epilepsy programs and research including $13 million for the CDCs Epilepsy program, $49 billion for the NIH, $5 million for the National Neurological Conditions Surveillance System and increased funding for the Social Security Administration.
-Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023, support $19 million for the VA Epilepsy Centers of Excellence.
-Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2023, support $3.653 billion for the Food & Drug Administrations BA.
-Defense Appropriations Act, 2023, support robust funding for epilepsy-related research through the Congressionally Directed Medical Research Programs.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Weidner |
|
|
|
Rachel |
Patterson |
|
|
|
Tyler |
Beck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
-Reconciliation legislation, support additional funding for Medicaid home- and community-based services; addressing affordability of health insurance premiums; creating an out-of-pocket cap in Medicare Part D with smoothing mechanism; bar use of discriminatory quality-adjusted life year (QALY) in prescription drug legislation; preserving the Orphan Drug Tax Credit; expand Medicaid.
-S. 3799 PREVENT Pandemics Act, incorporate disability into pandemic preparedness legislation Work has stalled on this, we had success in committee but havent done much on it since we could take it out
-S. 464/H.R. 2163, Safe Step Act, support passage.
-S. 253, Marihuana Research Expansion Act and H.R. 5657, Medical Marijuana Research Act, support passage.
-Identify and make recommendations on improvements to federal law for access to medical cannabis and medical cannabis products.
-H.R. 5435, BRAIN Act, S. 3427, Neuroscience Center of Excellence Act and H.R. 6000, Cures 2.0 Act, support creation of a Neuroscience Center of Excellence at the FDA that is patient-focused and related necessary appropriations.
- S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 / H.R. 7667 Food and Drug Amendments Act of 2022, ensure that any new regulation of dietary supplements protects access to CBD, support amendment to ban use of certain electric shock devices, support provisions regarding diverse enrollment in clinical trials, support provisions to support orphan drug development
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Weidner |
|
|
|
Rachel |
Patterson |
|
|
|
Tyler |
Beck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |